Guangshengtang and other 10 pharmaceutical stocks rose to the limit, and the industry believes that the sector will meet the opportunity

On December 16, the pharmaceutical and biological industry rose by 1.
30%, and 10 stocks rose to the limit, including Guangshengtang, Luoxin Pharmaceutical, China Pharmaceutical, Lisheng Pharmaceutical, Minova, etc
.
From the perspective of growth, among them, as of the close of December 16, Guangshengtang closed at 48.
6 yuan, an increase of 20.
00%, with a volume of 24.
5133 million shares, a turnover of 1145.
0116 million yuan, and a turnover rate of 18.
40%.

The unit is a hot stock
of hepatitis concept + innovative drug concept.
The company focuses on the field of liver health, and the first subject in the phase I clinical trial of GST-HG151, a new drug for the treatment of non-alcoholic steatohepatitis and liver fibrosis of Fujian Guangsheng Zhonglin Biotechnology Co.
, Ltd.
, a subsidiary of its innovative drug holding company, was successfully enrolled in the drug administration on March 11, 2022, marking that the clinical trial of GST-HG151 project has entered the substantive development stage
。 In addition, in December 21, Fujian Guangsheng Zhonglin Biotechnology Co.
, Ltd.
, a holding subsidiary, signed a "cooperative development contract" with Shanghai WuXi AppTec New Drug Development Co.
, Ltd.
for oral small molecule 3-CL (3C-like) protease inhibitors in a class of new drug research and development projects
.
It was followed by Luoxin Pharmaceutical, which closed 10.
06% at the close of trading on December 16 at 8.
97 yuan
.
The analysis believes that the reason category of the stock is traditional Chinese medicine + pharmaceutical business + influenza + Internet medical treatment
.
The pharmaceutical business sector is a major business of the company, which mainly provides comprehensive services of drugs, medical devices, Chinese medicine pieces, health food and Internet + smart medical care; The engineering construction project of traditional Chinese medicine industrial base of Shandong Luoxin Lekang Pharmaceutical Co.
, Ltd.
invested and constructed by it has been put into production, and the company has obtained more than ten varieties of production approvals such as montmorillonite powder, throat cleansing and pharyngeal compound, cold cough granules, and cough syrup and have been put on the market
.
In addition, the company's production of Ambroxol hydrochloride is a class of expectorants
.
It is worth mentioning that many pharmaceutical stocks that have recently set off a wave of ups and downs have risen again, for example, China Pharmaceutical closed again on December 16, with its stock price rising 10.
03% and closing at 20.
30 yuan
.
The stock is a blood product, pharmaceutical concept hot stock, the company's pharmaceutical business sector layout is deep, the shareholding company Shanghai emerging blood products products are rich
.
IN ADDITION, IN MARCH 22, THE COMPANY SIGNED AN AGREEMENT WITH PFIZER TO BE RESPONSIBLE FOR PFIZER'S COMMERCIAL PRESENCE IN THE Chinese mainland MARKET DURING THE AGREEMENT PERIOD (2022
).
For example, Xinhua Pharmaceutical's closing limit on December 16 was also up and down, and the stock price rose 10.
00% at the close, closing at 46.
10 yuan
.
The analysis believes that this is mainly related to Xinhua Pharmaceutical is an antipyretic and analgesic drug manufacturer, and the company's main products include antipyretic and analgesic APIs, tablets, injections, capsules, and pharmaceutical intermediates
.
Recently, the market sales of ibuprofen are overheated and in short supply, and Xinhua Pharmaceutical is the head enterprise of domestic ibuprofen, in addition to ibuprofen, Xinhua Pharmaceutical also has aspirin, metamizole sodium, aminopyrine, antipyrine, isoproantipyrine, tramadol, meloxicam and other varieties
.
In addition, the company signed a strategic cooperation agreement with Real Biologics, and Real Biologics agreed that Xinhua Pharmaceutical is a manufacturer and distributor of azvudine and other products owned by Xinhua Pharmaceutical in China and other countries agreed by both parties; Suntec Pharmaceutical, a wholly-owned subsidiary of the Company, has obtained the qualification
of marketing authorization holder of ursodeoxycholic acid tablets, a drug for the treatment of cholesterol-type gallstones.
The industry believes that the current pharmaceutical sector is facing the opportunity to layout, among which innovative drugs, medical devices, pharmacies, etc.
can be focused on
in subdivided tracks.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.